4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
GlaxoSmithKline Pharmaceuticals Limited (GLAXO) operates in the Drug Manufacturers - General industry and is headquartered in Mumbai, India with about 3,103 employees. Its market capitalization is roughly ₹481 billion. In the fiscal year ended 2026-03-31, GLAXO reported ₹38.1B in revenue and ₹10.4B in net income.
GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers adult and pediatric vaccines, such as Shingrix, Havrix, Fluarix Tetra, Varilrix, Infanrix Hexa, Boostrix, Synflorix, Menveo, and Priorix.
Interactive charts & full statements →
| Income statement | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Revenue | ₹38.1B | ₹37.3B | ₹34.4B | ₹32.3B | — |
| Gross Profit | ₹23.9B | ₹22.5B | ₹20.2B | ₹18.7B | — |
| Operating Income (EBIT) | ₹12.5B | ₹11.1B | ₹8.4B | ₹7.5B | — |
| Net Income | ₹10.4B | ₹9.3B | ₹5.9B | ₹6.1B | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | ₹9.4B | ₹10.0B | ₹10.4B | ₹8.1B | ₹9.7B |
| Gross Profit | ₹6.1B | ₹6.5B | ₹6.8B | ₹5.2B | ₹6.2B |
| Operating Income (EBIT) | ₹2.8B | ₹3.4B | ₹3.5B | ₹2.4B | ₹3.2B |
| Net Income | ₹2.4B | ₹2.8B | ₹3.0B | ₹2.1B | ₹2.6B |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Dividends Paid | (₹7.1B) | (₹7.5B) | (₹5.4B) | (₹15.3B) | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|
| Total Assets | ₹43.2B | ₹41.1B | ₹35.6B | ₹33.3B | — |
| Total Liabilities | ₹20.6B | ₹21.6B | ₹17.8B | ₹15.9B | — |
INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive GLAXO viewer.
This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी
About TickerBase · Data methodology & sources · Privacy · Terms